Recombinant Rat IL-17E Protein Summary
Product Specifications
Val17-Ala169
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
8949-IL
| Formulation | Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 100 μg/mL in 4 mM HCl containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
8949-IL/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in HCl with Trehalose. |
| Reconstitution | Reconstitute at 100 μg/mL in 4 mM HCl. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: IL-17E/IL-25
The Interleukin-17 (IL-17) family of proteins are immunoregulatory cytokines that share a conserved cysteine-rich region. IL-17E, which is also known as IL-25, promotes Th2-biased immune responses. This is in contrast to other IL-17 family members which promote Th1- and Th17-biased inflammation. IL-25 is an important mediator of allergic reactions and protection against intestinal parasites (1, 2). Mature rat IL-25 shares 80% and 91% amino acid sequence identity with mouse and human IL-25, respectively (3, 4). During helminth infections and allergic reactions, IL-25 is locally up-regulated in intestinal and airway epithelial cells, atopic dermatitis skin lesions, and local Th2 cells, eosinophils, and basophils (4-9). It binds to IL-17 RB but also requires IL-17 RA to exert its activity (3, 8, 10). IL-25 acts on a variety of cell types which respond with increased production of Th2 cytokines (e.g. IL-4, IL-5, IL-13) and reduced production of Th1 and Th17 cytokines (e.g. IFN-gamma, IL-12, IL-23, IL-17A, IL-17F) (4-6, 8, 9, 11-15). Airway IL-25 can be activated by MMP-7, a protease that is up-regulated in airway epithelium in response to allergen exposure (16). Cleaved IL-25 shows enhanced binding to IL-17 RB and stronger induction of Th2 cytokines (16). The Th2 cytokines, in turn, trigger expansion of Th2 memory cells and anti-inflammatory M2 macrophages, increased eosinophil mobilization and activation, and dendritic cell migration (4, 6, 9, 13). These actions promote protective anti-helminth immune responses (4, 5) as well as allergic inflammation and airway hyperreactivity (11). The IL-25 induced suppression of Th1 and Th17 cytokines limits Th17 cell expansion and disease pathology in autoimmunity and colitis (12, 15). IL-25 also promotes vascular endothelial cell proliferation and assembly into tubular structures (7). It supports the integrity of the blood-brain barrier and limits CD4+ T cell infiltration into the brain (17).
- Saadoun, D. et al. (2011) Curr. Pharm. Des. 17:3781.
- Iwakura, Y. et al. (2011) Immunity 34:149.
- Lee, J. et al. (2001) J. Biol. Chem. 276:1660.
- Fort, M.M. et al. (2001) Immunity 15:985.
- Zhao, A. et al. (2010) J. Immunol. 185:6921.
- Suzukawa, M. et al. (2012) J. Immunol. 189:3641.
- Corrigan, C.J. et al. (2011) Proc. Natl. Acad. Sci. USA 108:1579.
- Petersen, B.C. et al. (2012) Nat. Med. 18:751.
- Wang, Y.-H. et al. (2007) J. Exp. Med. 204:1837.
- Rickel, E.A. et al. (2008) J. Immunol. 181:4299.
- Hurst, S.D. et al. (2002) J. Immunol. 169:443.
- Kleinschek, M.A. et al. (2007) J. Exp. Med. 204:161.
- Cao, Q. et al. (2011) J. Am. Soc. Nephrol. 22:1229.
- Stock, P. et al. (2009) J. Immunol. 182:5116.
- Caruso, R. et al. (2009) Gastroenterology 136:2270.
- Goswami, S. et al. (2009) Nat. Immunol. 10:496.
- Sonobe, Y. et al. (2009) J. Biol. Chem. 284:31834.
Citation for Recombinant Rat IL-17E Protein
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Tumor suppressor p53 regulates intestinal type 2 immunity
Authors: CY Chang, J Wang, Y Zhao, J Liu, X Yang, X Yue, H Wang, F Zhou, JM Inclan-Ric, JJ Ponessa, P Xie, L Zhang, MC Siracusa, Z Feng, W Hu
Nature Communications, 2021-06-07;12(1):3371.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Rat IL-17E Protein
There are currently no reviews for this product. Be the first to review Recombinant Rat IL-17E Protein and earn rewards!
Have you used Recombinant Rat IL-17E Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
